IMGN - ImmunoGen bags priority review for full approval of ovarian cancer drug
2023-12-05 06:55:07 ET
More on ImmunoGen
- AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time
- Immunogen's AbbVie Deal: Key Insights For Investors And Traders
- AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology
- Barclays cuts ImmunoGen to equal weight, doesn't see more bidders
- Biotechs post record gains in November amid improving outlook
For further details see:
ImmunoGen bags priority review for full approval of ovarian cancer drug